Motoneurone Disease Stroke Peripheral Neuropathy Multiple Sclerosis
Drug Platform Publications Collaborations
Our Mission Management Team Advisory Boards


CuroNZ News

CuroNZ is pleased to report high level pre-clinical results achieved in patient dog studies in collaboration with Dr Roger Clemmons, Associate professor of Neurology for animals at the University of Florida.  He has applied intra-muscular NRP injections to several patient dogs suffering from spinal cord injury, eye diseases and the dog equivalent of progressive Multiple Sclerosis (degenerative myelopathy). 

We have uploaded a video of ‘Buc’ the dog who has spinal cord injury and the dog equivalent of retinitis pigmentosa, the video shows before and after NRP walking, gait and movement.  Click to view Video. 

Since having NRP injections Buc's eyesight has not deteriorated as would normally be expected in this timeframe and as you can see on the video his gait and walking is much improved.

Due to NRPs regenerative properties, it has the potential to be efficacious for many central nervous system diseases.

Some of CuroNZ's target diseases are the following:

Disease

Cases Per Year (USA)

Market Size in US$

Effective
Treatments available?

Motoneurone Disease

6000

$150m

No

Stroke

800,000

$3.5b

No

Multiple Sclerosis

800,000

$2.5b

Yes and No

Traumatic Brain Injury

1,000,000

$1b

No

Peripheral Neuropathy

20,000,000

$50b

Yes and No

CNS Biology

CNS Biology

"Pearl-chain" like migration

"Pearl Chain" like Migration

Diagram showing NRP provoking a “pearl-chain”-like migration (arrows) over a few millimeters originating from the thalamic tissue heading towards neocortical tissue. 

The in vitro  assay  used postnatal rat CNS-derived brain slices cultivated on coverslips.

Read more about: